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Several distinct innate lymphoid cell (ILC) populations have been recently identified and
shown to play a critical role in the immediate immune defense. In the context of tumors,
there is evidence to support a dual role for ILCs with pro- or antitumor effects, depending
on the ILC subset and the type of cancer. This ambivalent role has been particularly
well-described in colorectal cancer models (CRC), but the presence and the evolution
of ILCs in the peripheral blood of metastatic CRC (mCRC) patients have not yet been
explored. Here, we investigated the distribution of ILC subsets in 96 mCRC patients who
were prospectively included in the “Epitopes-CRC02” trial. Peripheral bloodmononuclear
cells (PBMCs) were analyzed by flow cytometry at metastatic diagnosis and after
3-months of treatment. The treatments consisted of Oxaliplatin-based chemotherapies
for 76% of the patients or Folfiri (5FU, Irinotecan) chemotherapies for 14% of patients.
Compared to healthy donors, the frequency of total ILCs was dramatically increased at
metastatic diagnosis. CD56+ ILC1-like cells were expanded, whereas ILC2, NCR− ILCP
and NCR+ ILCP subsets were decreased. Combined analysis with the systemic
anti-telomerase hTERT Th1 CD4 response revealed that patients with low anti-TERT
Th1 CD4 responses had the highest frequencies of total ILCs at diagnosis. Of those,
91% had synchronous metastases, and their median progression-free survival was 7.43
months (vs. 9.17 months for the other patients). In these patients, ILC1 and ILC2
were significantly decreased, whereas CD56+ ILC1-like cells were significantly increased
compared to patients with low frequency of total ILCs and high anti-TERT responses.
After treatment, the NCR+ ILCP were further decreased irrespective of the chemotherapy
regimen, whereas the balance between ILC1 and CD56+ ILC1-like cells was modulated
mainly by the Folfiri regimen in favor of ILC1. Altogether our results describe the effects of
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different chemotherapies on ILCs in mCRC patients. We also establish for the first time a
link between frequency of ILCs and anti-tumor CD4T cell responses in cancer patients.
Thus, our study supports an interest in monitoring ILCs during cancer therapy to possibly
identify predictive biomarkers in mCRC.
Keywords: ILC, metastatic colorectal cancer, Th1, chemotherapy, immunomonitoring
INTRODUCTION
Colorectal cancer (CRC) has been used as amodel to demonstrate
the role of the immune system in cancer, notably to establish
the prognostic role of memory T cell infiltration and Th17
predominance (1). Fifteen percent of localized CRC patients
present microsatellite instability (MSI), with a higher mutation
load conferring a higher response to immunotherapy (2). The
immune response is also involved in CRC microsatellite stability
(MSS), for example in consensus molecular subtype (CMS) four
CRC patients (3). Research at the metastatic stage is ongoing in
order to better define the CRC-stage-linked immune responses.
It was previously described that cytotoxic innate immune cells, so
called conventional natural killer (NK) cells, were almost absent
in human colorectal tumors, despite efficient T cell infiltration
(4). In contrast, a recent study on 13 localized human CRC and 13
lung tumors showed that helper innate immune cells, the recently
identified family of innate lymphoid cells (ILCs) are present in
these tumors, at different levels (5).
Distinct helper ILC populations have been reported to play
a critical role on the maintenance of tissue homeostasis and
immediate immune host defense (6). ILCs exhibit transcription
factor and cytokine profiles that phenocopy the three major T
helper (Th) cell subsets: Th1, Th2, and Th17/22. Thus, ILCs
are classified into three subgroups, ILC1, ILC2, and ILC3 (7–9).
The ILC3 subgroup can be further subdivided into NCR+ ILC3
that express the natural cytotoxicity receptor (NCR) NKp46,
and NCR− ILC3, which include lymphoid tissue inducer (LTi)
cells. In addition, an extensive analysis of ILC from human
peripheral blood and tissue showed recently that ILCs with c-
Kit+ phenotype, previously proposed to represent human ILC3,
are enriched in multi-potent and uni-potent ILC precursors
(ILCP) in the peripheral blood that can give rise to all know ILC
subsets (10).
ILCs produce high amounts of different cytokines very early
after infection and tissue damage, suggesting potential pro- and
anti-oncogenic roles of these cells during the early phases of
carcinogenesis. ILC1s represent a very early source of IFN-γ
that is mainly associated with a protective role against tumors
through the upregulation of MHC molecules (11–13), the
induction of Th1 polarization, and the activation of macrophages
(14). Recently, we identified CD56+ ILC1-like cells, an ILC
population within the ILC1 compartment, which constitutively
expresses CD56 and CD127, but lack c-Kit; similar to Stage 4b
NK cells they lack KIR and CD16, but they express NKG2A.
CD56+ ILC1-like cells possess cytotoxic potential and have anti-
leukemic effects (Salome et al., in revision). Similarly, CD103+
cytotoxic intraepithelial ILC1-like cells were previously reported
in localized colorectal tumors (5) and were shown to directly
kill tumor cells in a perforin-dependent manner (15, 16). Both
pro- and antitumor roles of ILC2 in cancer biology have been
suggested. Indeed, we and others reported on the expansion
of ILC2, which contributed to the suppression of antitumor
responses via an IL-13/monocytic-myeloid derived suppressor
cell (M-MDSC) axis (17–19). In CRC, high levels of the ILC2-
activating alarmin IL-33 and the prototypic ILC2 cytokine IL-
4 are associated with poor prognosis (20, 21). In addition to
this protumorigenic role, ILC2 also produce IL-5, which induces
the selective expansion of eosinophils (22) whose degranulation
has been shown to improve prognosis in various types of
cancer, including CRC (23). Furthermore, secretion of IL-13 by
ILC2 may promote the migration of activated DCs to tumor-
draining lymph nodes resulting in cytotoxic T cell activation
(24). ILC3 have also been described to play a protective role in
carcinogenesis by limiting tissue damage through the secretion
of IL-22 in a model of chronic colitis (25). However, IL-22
producing CCR6+ ILC3 may increase the tumorigenic potential
of colon cancer (26–28). NCR− ILC3-derived IL-22 can act on
colon epithelial cells to sustain tumor progression. Moreover,
IL-17 was shown to inhibit tumor progression by acting on
T cells (29) and to contribute to reduced tumor growth and
metastasis in mice inoculated with a colon cancer cell line (26).
Nevertheless, an IL-23-Th17 gene signature in resected CRC
was associated with a worse prognosis and found to predict
rapid progression to metastatic disease, which demonstrates the
potential pro-tumorigenic role of ILC3 (30).
These observations suggest the involvement of ILCs in
natural tumor immunity. Furthermore, while a putative role
for ILCs in mediating the effect of chemo-immunotherapy
was demonstrated in a mouse model of melanoma (31),
there is limited data available on the impact of anti-cancer
treatments on ILC frequency and phenotype in humans. A
recent study on human ovarian cancer reported that an ILC3-
like population that expresses IFN-γ and IL-22 suppressed the
activation and proliferation of tumor-infiltrating lymphocytes
(TIL) ex vivo, suggesting a potential benefit of depleting these
cells before TIL-based immunotherapy (32). In addition, a
link between the efficacy of immune checkpoint blockades
and ILCs is currently under investigation because ILC2 cells
have recently been shown to express PD-1 (33, 34). Moreover,
growing evidence suggests that chemotherapymay also modulate
ILC homeostasis, in particular by altering the composition of
commensal microbiota (35).
In this study, we assessed the modulation of ILC subsets in
parallel with antigen-specific CD4T cell responses in a large
cohort of metastatic CRC (mCRC) patients, at baseline and 3
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months postchemotherapy. Since human telomerase (hTERT)
is expressed in many cancer types and plays a crucial role
in oncogenesis by providing proliferation, survival and anti-
apoptotic signals necessary for tumor progression (36–38), we
used hTERT as a hallmark of cancer and as a universal tumor
antigen prototype (39–41). We monitored the systemic anti-
hTERT Th1 CD4 response and explored the relationship between
anti-hTERT responses and the ILC compartment. We report here
that ILCs are increased in favor of ILC1 in the peripheral blood
of chemotherapy-naïve mCRC patients, and that the frequency
of ILCs is negatively correlated with the cancer-specific Th1
immune response. Moreover, we observed that chemotherapy
regimens, especially Folfiri, act on specific ILC subsets without
affecting the total ILC population in the peripheral blood.
MATERIALS AND METHODS
Patients and Healthy Donors
Metastatic colorectal cancer patients were enrolled from
March 2013 to August 2016 in the “Epitopes-CRC02” trial
(NCT02817178), a French multicentric prospective study
assessing the impact of treatment on the CD4T cell response.
All patients were enrolled after signing an informed consent,
in accordance with French regulation, and after approval by
local and national ethics committees. All data were anonymized.
Overall population characteristics are summarized in Table S1.
For each patient, blood samples were collected before any
metastatic cancer specific treatment (baseline) and after 3
months of a chemotherapy-based regimen. The materials
used and analysis plan are illustrated in Figure 1. Briefly, we
monitored ILCs by flow cytometry in 86 patients at baseline
and 76 matched patients after chemotherapy. From the samples
collected after treatment, we retained data for patients receiving
the following chemotherapy-based regimens: (A) 5FU and
Irinotecan (Folfiri) (n = 19), (B) 5FU and Oxaliplatin (Folfox)
(n = 40), and (C) 5FU, Oxaliplatin and Irinotecan (Folfoxiri)
(n = 17). Patients treated with 5FU only, patients without
treatment data available or patients without available data at
baseline were removed from the analysis. Of note, we chose to
include five patients who received Oxaliplatin and Raltitrexed,
a folic acid analog that inhibits thymidylate synthetase similar
to 5FU, in the Folfox branch. A total of 86% of patients received
a bevacizumab regimen as well, regardless of the chemotherapy
protocol. For healthy donor controls, blood cells were collected
from anonymous donors at the Etablissement Français du Sang
(Besançon, France) and the Transfusion Interregionale CRS
(Lausanne, Switzerland) using an apheresis kit preparation, after
obtaining signed informed consent.
Cell Isolation
Peripheral blood mononuclear cells (PBMCs) were isolated from
peripheral blood of patients and healthy donors by density
centrifugation using a Ficoll gradient (GE healthcare). Cells
were maintained in RPMI (Gibco) supplemented with 8%
human serum, 100 U/ml penicillin-streptomycin (Invitrogen)
and nonessential amino-acids.
Antibodies
The following anti-human antibodies were used for the lineage
the cocktail: CD3-FITC, CD4-FITC, CD8a-FITC, CD14-FITC,
CD15-FITC, CD16-FITC, CD19-FITC, CD20-FITC, CD33-
FITC, CD34-FITC, FcεRI-FITC, and CD203c-FITC (all from
Biolegend). In addition, these anti-human antibodies were
used: CD335 (NKp46)-PE/Cy7, CD294 (CRTH2)-PE, CD127-
BV421 from Biolegend, CD56-APCeF780 from eBioscience,
and CD117 (ckit)-APC from BD Bioscience. For intracellular
transcription factor staining the following anti-human antibodies
were used: Tbet-PE/CF594, GATA3-PE/Cy7, and RORγt-PE
from BD Bioscience. Corresponding isotype control antibodies
were used as controls.
Staining and Flow Cytometry
To prepare for immunostaining, PBMCs were counted and
suspended in FACS buffer (1X PBS, 50µM EDTA, 0.2% BSA)
prior to labeling with appropriate antibodies for 30min in the
dark at 4◦C. The cells were then washed with 1X PBS. For the
second step, cells were stained with the fixable viability dye,
eFluor 506 (eBioscience), for 30min at 4◦C. The cells were then
washed again with 1X PBS. Samples were evaluated on a FACS
Canto II (BD Biosciences).
For transcription factor staining, after extracellular staining,
cells were fixed and permeabilised using the InvitrogenTM
eBioscience Foxp3/Transcription factor staining buffer Set
according to manufacturer’s recommendations. Intracellular
antibodies were prepared in Permeabilisation buffer 1X and the
intracellular staining was perform for 1 h at room temperature.
After incubation, cells were washed with Permeabilisation buffer
1x twice and finally resuspended in FACs buffer. Samples were
acquired using a Gallios II from Beckman Coulter.
Analysis were realized with FlowJo Software v 9.9.4. The
gating strategy was set based on the isotype controls and applied
in a standard format across all samples and all conditions.
Assessment of Spontaneous
hTERT-Specific CD4T Cell Responses in
Cancer Patients
An IFN-γ ELISpot was conducted for 74 patients of the cohort
at baseline, as previously described by Godet et al. (42). Briefly,
spontaneous responses were assessed by IFN-γ ELISpot after an
in vitro stimulation of PBMCs with a mixture of eight peptides
derived from hTERT (TERT44−58, TERT578−592, TERT921−935,
TERT1055−1069, TERT541−555, TERT573−587, TERT613−627, and
TERT911−925) at 5µg/ml for 10 days. Another peptide mixture,
referred to as CEF (PANATecs), derived from influenza virus
(Flu), Epstein Barr virus (EBV), and cytomegalovirus (CMV)
was used to evaluate antiviral recall responses in the same
patients. CEF IFN-γ ELISpot data were available for 69 of
the 74 patients. After the 10-day incubation with the peptide
mixtures, the cells (105 per well) were cultured in triplicate in
the ELISpot plate with restricted peptides mixture or individual
peptides at 5µg/mL in X-vivo 15 medium (Ozyme, BE04–
418) for 15 h. The IFN-γ spots were developed following the
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FIGURE 1 | Flowchart of available materials and analysis plan.
manufacturer’s instructions (Diaclone, 856 051 020P). Spot-
forming cells were counted using the C.T.L. Immunospot system
(Cellular Technology Ltd.). The number of specific T cells
expressed as the number of spot-forming cells per 105 cells
was calculated after subtracting the negative control values
(background). Responses were considered positive when the
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number of IFN-γ spots was >10 and greater than twice the
background. Responses with a background >100 spots were
excluded from the analysis.
Statistical Analysis
Numerical data are expressed as the mean ± SEM (Standard
Error Mean). Student’s t-tests, ANOVAs and Chi-square tests
were used for the evaluation of statistical significance, calculated
with GraphPad Prism 8.0 or R Studio. P-values lower than 0.05
were considered significant with ∗p < 0.05, ∗∗p < 0.005, ∗∗∗p <
0.001, and ∗∗∗∗p < 0.0001. Progression free survival (PFS) was
calculated from the date of study enrolment to the date of tumor
progression. Kaplan-Meier survival curves were generated using
R Studio R© software (median with 95% confidence interval).
RESULTS
Chemotherapy-Naïve Metastatic
Colorectal Cancer Patients Have Increased
Frequencies of ILCs and Their Subsets’
Distribution Is Skewed Toward ILC1
To evaluate the impact of mCRC on ILCs, we investigated ILC
frequency and subset distribution in PBMCs of 86 chemotherapy
naïve (baseline) mCRC patients included in the “Epitope-
CRC02” study (Table S1). Fifty-one healthy donors (HD) were
used as a control cohort. The percentage of total ILCs (ILCtot)
(Lin− CD127+) was assessed by flow cytometry, as well as the
five ILC subsets, defined as ILC1 (Lin− CD127+ cKit− CRTH2−
CD56−), CD56+ ILC1-like (Lin− CD127+ cKit− CRTH2−
CD56+), ILC2 (Lin− CD127+ CRTH2+), NCR− ILCP (Lin−
CD127+ cKit+ NKp46−), and NCR+ ILCP (Lin− CD127+ cKit+
NKp46+) (Figure 2A and Figure S1A). In addition, we validated
our gating strategy by assessing master transcription factor
expression of each population by flow cytometry (Figure S1B).
For ILC2, functionally distinct c-Kit+ and c-Kit− ILC2 have
recently been described in healthy donors (43). Interestingly, in
mCRC patients ILC2 were almost exclusively c-Kit− (Figure S2).
Thus, in subsequent analysis, ILC2 were analysis only based
on the expression of CRTH2. We observed that the frequency
of ILCtot are significantly increased in the PBMCs of mCRC
patients at baseline compared to HD (Figure 2B). Moreover, the
distribution of the ILC subsets was also distinct in chemotherapy-
naïve mCRC patients (Figures 2C,D). The ILC2, NCR+ ILCP
and NCR− ILCP subsets were significantly decreased in patients
at baseline compared to HD, whereas the ILC1 and CD56+
ILC1-like subsets were increased. We next stratified the patients
according to their total ILC tercile distribution: ILCtot low
[0.09–0.54%], n = 29; ILCtot medium [0.54–0.96%], n = 29;
and ILCtot high [0.99–4.11], n = 28. For each group, the ILC
subset distribution was analyzed, and the results showed that the
ILC subset proportions are linearly modulated (Figures 2E,F).
Deeper analysis revealed that the ILC1 population proportion
was significantly decreased in ILCtot high patients, whereas
CD56+ ILC1-like cell proportion was increased. Of note, ILCtot
low patients had the highest proportion of NCR− ILCP and
NCR+ ILCP cells. Overall, these results show that ILCs are
drastically increased in the peripheral blood, with a skewing
toward ILC1s at CRC metastatic diagnosis. Moreover, patients
with high proportions of ILCtot present the lowest rates of ILC1
and NCR− ILCP cells in favor of CD56+ ILC1-like cells.
Patient Clinicobiological Characteristics
and ILC Distribution
To evaluate the link between ILCs and clinicobiological data we
focused our analysis on 74 patients for which ILC frequencies
and tumor-specific Th1 immunity (focusing on hTERT as a
universal tumor-antigen) were available. The clinicobiological
characteristics available for these patients are summarized in
Table 1. Because we observed that ILCtot high patients presented
at least 2-fold more ILCs than HD, for clinical correlations
we decided to perform our analyses with merged ILCtot
medium and ILCtot low patients (referred to hereafter as ILCtot
low) (Table 1). ILCtot high patients did not differ from the
rest of the cohort with regards to the age, gender, tumor
location, time of metastases or metastatic location. Regarding
biological and molecular parameters, no difference was observed
between the two groups. Of note, ILC counts were not
influenced by microsatellite status, RAS and BRAF mutations,
carcinoembryonic antigen (CEA) value or lymphocyte count.
Interestingly, only 13% of MSI tumors had an ILCtot high
phenotype and the BRAF mutation prognostic biomarker was
not enriched in the ILCtot high patients. Tumor response rate
was also not different based on the profile of ILC distribution.
Next, some hypotheses were formulated regarding the
different subsets of ILCs and were subsequently tested with
our data. (i) We first hypothesized that MSI CRC patients
harbor a higher mutational load and an interferon gamma
(IFN-γ) signature. However, we observed that ILC subsets were
distributed equally in the nine MSI tumors (data not shown),
with the ILC1 subset count higher in only two patients. (ii) Next,
inflammatory contextures, such as mucosal immunity or hepatic
metastatic localization, were specifically assessed for ILC subsets.
In the 68 synchronic patients with a primary colon tumor in
place, the ILC subset proportions were largely the same. The
ILC subset proportions were almost equally distributed among
each different subset. (iii) We then hypothesized that cytokine
availability following lymphopenia could enhance the number of
ILCs, as has been described for NK cells after transplantation
(44, 45). However, here we did not observe such an expansion,
regardless of which ILC subset was considered. (iv) BRAF
mutations are present in 5–8% of mCRC patients and are often
associated with MSI tumors, however, less is known about BRAF
mutations in MSS tumors. Of the nine BRAF mutated patients in
our cohort, three had an MSS phenotype, however, none of these
patients presented any specific enrichment for one ILC subset.
ILCs Are Negatively Correlated With the
Th1 Anti-hTERT Immune Response
To explore the relationship between the adaptive immune
system and ILCs, we took advantage of promiscuous hTERT-
derived MHC class II peptides that allow for monitoring of
anti-telomerase Th1 CD4 immunity in most HLA contexts
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FIGURE 2 | Distribution of ILCs in healthy donors and in metastatic colorectal cancer patients. (A) Flow cytometry gating strategy for ILC subset identifications in
PBMCs. (B) Frequencies of ILCtot. ILC subset distributions (C) and frequencies (D) were analyzed by flow cytometry in PBMCs of 51 healthy donors (HD) and 86
chemotherapy-naïve metastatic colorectal cancer patients (baseline). Distribution (E) and frequencies (F) of ILC subsets based on the frequency of ILCtot distributed
in the low (n = 29), medium (n = 29), and high (n = 28) terciles. Columns, the means of ILC frequency for each patient; bars, SEM. *p < 0.05, **p < 0.005, ****p <
0.0001, as determined by Student’s t-test or ANOVA.
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ILC low ILC high p
n = 74 (%) n = 50 (%) n = 24(%)
AGE-YEARS
<65 n = 36 (49%) 22 (44%) 14 (61%)
≥65 n = 37 (51%) 28 (56%) 9 (49%) 0.28
GENDER
F n = 27 (36%) 16 (32%) 11 (46%)
M n = 47 (64%) 34 (68%) 13 (54%) 0.37
TUMOR LOCATION
Rectum n = 19 (27%) 14 (30%) 5 (21%)
Colon n = 52 (73%) 33 (70%) 19 (79%) 0.60
MICROSATELLITES
MSI n = 8 (21%) 7 (28%) 1 (7%)
MSS n = 31 (79%) 18 (72%) 13 (93%) 0.26
RAS STATUS
M n = 33 (50%) 20 (45%) 13 (59%)
WT n = 33 (50%) 24 (55%) 9 (41%) 0.43
BRAF STATUS
M n = 8 (14%) 5 (11%) 3 (14%)
WT n = 58 (86%) 39 (89%) 19 (86%) 0.99
TIME OF METASTASIS
Metachronous n = 14 (20%) 12 (24%) 2 (8%)
Synchronous n =57 (80%) 35 (76%) 22 (92%) 0.16
METASTATIC LOCALIZATION
Extra hepatic n = 16 (22%) n = 14 (29%) n = 2 (8%)
Hepatic and other n = 19 (26%) n = 12 (25%) n = 7 (29%)





n = 35 (49%) n = 26 (54%) n = 9 (37.5%)
Hepatic only n = 37 (51%) n = 22 (46%) n = 15 (62.5%) 0.28
LYMPHOCYTE COUNT
<1,000 n = 9 (13%) 5 (11%) 4 (17%)
≥1,000 n = 61 (87%) 41 (89%) 20 (83%) 0.75
ACE
<20 n = 26 (43%) 19 (46%) 7 (35%)




n = 4 (7%) 2 (5%) 2 (10%)
Stable disease n = 21 (36%) 13 (35%) 8 (40%)
Partial response n = 29 (50%) 21 (55%) 8 (40%)
Complete
response
n = 4 (7%) 2 (5%) 2 (10%) 0.66
The ILCtot frequencies of patients at baseline were distributed into terciles. The results
shown for the low (n = 25) and medium (n = 25) terciles were pooled and referred to as
ILC low (n = 25 + 25 = 50), and the high tercile was referred to as ILC high (n = 24).
ELISpot hTERT response data was available for all 74 patients, however, data for some
clinicobiological characteristics are missing for some patients.
(42, 46, 47). For this purpose, IFN-γ production by PBMCs
derived from 74 chemotherapy naïve mCRC patients exposed
to hTERT promiscuous peptides was measured by ELISpot in
short-term stimulation assays. hTERT-derived peptides were
recognized by PBMCs from 18 of the patients analyzed (24.3%)
(Figure 3A). A trend of lower frequency of ILCs was observed
in these patients in comparison to the mCRC patients who had
no Th1 responses after hTERT-peptide stimulation. For each
ILCtot group, the number of IFN-γ spots after MHC class II
restricted hTERT peptide stimulation were analyzed (Figure 3B).
Interestingly, ILCtot low patients had a higher anti-telomerase
Th1 response compared to patients with high ILC levels. As
a comparison to the cancer antigen hTERT, we concurrently
measured T cell reactivity against a mixture of viral peptides in
the same patient group (Figure 3C). Anti-viral T cell responses
were detected in most patients (76.8%). Unlike the systemic
anti-hTERT Th1 response, the frequency of patients exhibiting
antiviral T cell responses was equally distributed among the
patient subgroups. These results suggest that the presence of
circulating anti-hTERT Th1 responses is related to the ILCtot
proportion. Interestingly, regardless of the ILCtot percentage,
patients with the highest proportion of ILCP had a better Th1
response compared to patients with the lowest NCR+/− ILCP
proportion (Figure 3D).
To explore the prognostic value of ILCtot high patients having
lower anti-hTERT Th1 responses, we estimated the PFS of the
ILCtot high and ILCtot low patients (Figure S3). In our cohort,
the median of PFS was 7.43 months (95% CI: 6.44–14) for the
ILCtot high patients, and 9.17 months (95% CI: 7.62–11.8) for
the ILCtot low patients (p = 0.3). A better prognosis tendency
was observed for the ILCtot low patients in our cohort, especially
after 15 months.
Our results show that the frequency of ILCtot in the peripheral
blood of mCRC patients at baseline is negatively correlated with
anti-hTERT Th1 immune responses.
Chemotherapy Treatment of mCRC
Modulates ILC Subsets’ Distribution
Most conventional chemotherapies present immunogenic
properties that at least partially contribute to their clinical
efficacy (48). To evaluate the impact of chemotherapies on
ILCs, we performed a comparative analysis of total and
ILC subset frequency in peripheral blood of chemotherapy
naïve mCRC patients at baseline and on the same patients
after 3 months of treatment (TT in Figure 4) with the
classical chemotherapy regimens, Folfiri (5FU and Irinotecan;
n = 19), Folfox (5FU and Oxaliplatin; n = 40), and Folfoxiri
(5FU, Oxaliplatin and Irinotecan; n = 17). The results
showed that chemotherapies did not affect the frequency of
total ILCs, which remain high after treatment (Figure 4).
However, chemotherapies modulated the distribution of
ILC subsets. The Folfiri regimen significantly reversed the
balance between ILC1 and CD56+ ILC1-like cells, while
ILC2 were not affected by any of the treatments. All of
the regimens induced a decrease in NCR+ ILCP that
reached significance in the Folfox group, whereas NCR−
ILCP were significantly increased in the Folfoxiri group.
Collectively, these data highlight the ILC modulation potential
of chemotherapy treatments.
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FIGURE 3 | IFN-γ ELISpot hTERT responses relative to the distribution of ILCs. PBMCs from 74 chemotherapy-naïve metastatic colorectal cancer patients were
cultured with a mixture of 8 hTERT peptides (TERT44−58, TERT578−592, TERT921−935, TERT1055−1069, TERT541−555, TERT573−587, TERT613−627, and
TERT911−925) at 5µg/mL. The T cell reactivity against the hTERT peptides was detected by IFN-γ ELISpot assays, as described in the Material and Methods.
Stimulation with Viral Ag-CEF peptides was used as control for T cell reactivity. (A) The frequency of ILCtot in the PBMCs of each patient was analyzed based on the
positive (n = 18) or negative (n = 56) response to hTERT. (B,C) Results are shown as the means of IFN-γ spot numbers (magnitude) and the ILC frequencies (ILCtot
distributed into low (n = 25), medium (n = 25) and high (n = 24) terciles) for hTERT responses (B) and Viral Ag-CEF responses (C). (D) Results are shown as the
means of IFN-γ spot numbers (magnitude) and frequencies of NCR− ILCP (left) and NCR+ ILCP (right) distributed among the low (n = 25), medium (n = 25) and high
(n = 24) terciles. Columns, the means of spots from triplicate wells; bars, SEM. *p < 0.05, as determined by Student’s t-test.
DISCUSSION
ILC dysregulation in terms of frequency and subset composition
has already been described in hematological malignancies and
some solid tumors (18, 19, 49–51). Here we analyzed ILC
populations in mCRC patients pre- and postchemotherapy. We
showed that ILCtot are drastically increased in the peripheral
blood, suggesting cytokine stimulation in the ILC compartment.
IL-7, largely described as a key stimulator of ILC proliferation
and survival (52), could play such a role. Indeed, IL-7 was
recently described as particularly elevated in the serum of CRC
patients, especially in patients with metastases (53). Deeper
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FIGURE 4 | Effect of chemotherapy treatments on ILC distribution. Frequencies of ILCtot (A) and ILC subsets (B) were analyzed by flow cytometry in PBMCs from
chemotherapy-naïve mCRC patients (baseline) and after 3 months of treatment (TT). The mean frequency of ILCtot for HD is represented by a dashed line. Each
patient received either the 5FU/Irinotecan regimen (Folfiri) (baseline/TT matched patients, n = 19), the 5FU/Oxaliplatin regimen (Folfox) (baseline/TT matched patients,
n = 40), or the 5FU/Oxaliplatin/Irinotecan regimen (Folfoxiri) (baseline/TT matched patients n = 17). *p < 0.05, **p < 0.005, as determined by Student’s t-test.
analysis revealed that the distribution of ILC subsets was altered
in CRC patients. Indeed, only ILC1 and CD56+ ILC1-like
cells were increased in mCRC patients at baseline compared
to HD, whereas ILC2 and especially NCR− ILCP and NCR+
ILCP were decreased. Recently, increased TGF-β in the tumor
microenvironment was described as a key factor driving immune
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evasion andmetastases in CRC (54). Interestingly, the conversion
of NK cells into noncytotoxic ILC1 has been reported as a novel
mechanism of tumor immune escape, being dependent on TGF-
β (55, 56). Indeed, the plasticity of ILCs could impact their role
in cancer development. Collectively, these data suggest that ILC1
and ILC1-like cells could be increased due to TGF-β in mCRC
patients. Further investigations are necessary to understand if
the plasticity of ILCs is involved in this conversion or if the
proliferation of CD56+ ILC1-like cells is specifically favored.
Immunity against cancer is mainly mediated by Th1 cells
(57, 58). Th1 immune infiltration is correlated to a better
prognosis for patients, notably in CRC. The molecular analysis
of cytotoxic and helper T cell populations in 125 colorectal
tumor specimens by Galon et al. (30) showed that patients
with high Th1 cluster expression have prolonged disease-free
survival. More recently, data suggested that circulating tumor-
specific T cells might reflect in situ events in the tumor (59, 60),
since cancer immunity is a dynamic process that involves cell
trafficking through the peripheral blood. Our results showed
that higher systemic IFN-γ Th1 responses correlated with a
lower frequency of total ILCs, but higher proportions of ILCP
subsets. Thus, IFN-γ produced by ILC1 could drive the adaptive
response toward a cancer specific Th1 profile. ILCP cells seem
to also be associated with the Th1 immune response because the
highest proportions of ILCP cells were found in patients with
the strongest Th1-derived IFN-γ responses. It has been recently
reported that NCR+ ILCP cells are increased in human non-
small cell lung cancer (NSCLC) tissue and might contribute to
the formation of protective tumor-associated tertiary lymphoid
structures (61). These observations might explain the specific
increase in anti-tumor CD4T cell responses.
Even if no significant PFS differences could be observed when
comparing ILCtot low vs. high patients, there was a tendency for
higher PFS in ILCtot low patients with high Th1 hTERT-related
responses. These observations are in line with previous studies
where spontaneous universal cancer peptide (UCP)-specific T-
cell immune responses correlated with increased overall survival
of patients responding to chemotherapy in NSCLC and anal
squamous cell carcinoma (42, 62). Interestingly, no significant
differences were observed between each group regarding the
clinicobiological characteristics. However, it is interesting to note
that the ILCtot high group was composed of only 13% MSI
tumors, even if these observations are based on a few patients
and considering that MSI tumors are rare in metastatic setting.
In addition, MSI is known to increase the T cell repertoire
involved in tumor immunity conferring a higher response to
immunotherapy (2).
The immune contexture determined at diagnosis influences
the prognosis of cancer patients, including patients with CRC
(63). Moreover, it turned out that widely used conventional
chemotherapies modulated the composition and functionality
of tumor immune infiltrates and this affected disease outcome
(48, 64). In addition, even if chemotherapy causes massive
lymphodepletion, this could ultimately reset the immune system
by favoring a rebound replenishment of various immune cell
subsets and/or allow the emergence of a specific effector
cell type with anticancer activity (65, 66). In this study, we
explored the effects of chemotherapy regimens on the ILC
compartment and we showed that the balance between NCR+
ILCP and NCR− ILCP was modulated. Indeed, NCR+ ILC3
were decreased with all regimens, and especially with Folfox,
whereas NCR− ILCP were increased especially with Folfoxiri.
Both regimens include Oxaliplatin, an agent already described
to be an activator of tumor-targeting immune responses, mainly
through the induction of immunogenic cell death (67). Folfiri
does not include Oxaliplatin and is less commonly described as
an immunologic modulator. However, Folfiri regimens induced
a decrease in CD56+ ILC1-like cells in favor of ILC1 cells.
Interestingly, Folfiri has been described to support the expansion
of circulating myeloid-derived suppressor cells (MDSCs), while
this is not the case for Folfox (68). Thus, it would be interesting
to explore the relationship between ILC1/ILC1-like cells and
MDSCs in the context of mCRC.
To conclude, this study showed that ILCs are increased in
the peripheral blood of chemotherapy-naïve mCRC patients
and that their subset distribution is modulated. Moreover, the
frequency of ILCs was found to be negatively correlated with
the cancer-specific Th1 immune response. Finally, we showed
that chemotherapy regimens act on the ILC compartment,
especially Folfiri treatment, which modulated the balance
between ILC1 and ILC1-like cells. Altogether, these results
highlight the importance of considering the ILC compartment in
the monitoring of immune responses in cancer to better define
immune scores and eventually to identify useful biomarkers.
ETHICS STATEMENT
This study was carried out in accordance with the
recommendations of ANSM (Agence Nationale de Sécurité
du Médicament et des produits de santé; no. 2012-A01377-36)
with written informed consent obtained from all subjects in
accordance with the Declaration of Helsinki. The protocol was
approved by the independent Est-II French Committee for the
Protection of Persons no. 12/672.
AUTHOR CONTRIBUTIONS
RL, BS, AG-C, and ST conducted the experiment. RL and MJ
carried out data analysis. RL, MJ, CB, and CJ designed the
research study. RL, MJ, BS, JG, MK, PR, ST, OA, CB, and CJ
discussed the results, and wrote and/or reviewed the manuscript.
FUNDING
This work was supported by the Swiss National Science
Foundation (SNSF), the Swiss Cancer League, the Fondation pour
la recherche Nuovo-Soldati, La Ligue contre le cancer, and the
Interregional Programme Hospitalier pour la Recherche Clinique.
ACKNOWLEDGMENTS
We are grateful to the patients for their dedicated
collaboration and to the healthy donors for their blood and
Frontiers in Immunology | www.frontiersin.org 10 September 2019 | Volume 10 | Article 2121
Loyon et al. ILC in Metastatic Colorectal Cancer
tissue donation. We especially thank the Biomonitoring
Platform of CHU Besançon for their management of
patient samples.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fimmu.
2019.02121/full#supplementary-material
Figure S1 | Flow cytometry gating strategy and expression of transcription factors
for human ILC subsets. (A) Flow cytometry gating strategy for ILC subset
identifications in PBMCs of a representative HD and a representative mCRC
patient. (B) Transcription factors T-bet, GATA3 and RORγt were assessed by
intracellular staining respectively on ILC1 and CD56+ ILC1, ILC2, and ILCP.
Representative example of the staining on PBMCs of a healthy donor. Gray
histograms correspond to the FMO.
Figure S2 | Distribution of ILC2 c-Kit− and c-Kit+ in healthy donors and
metastatic colorectal cancer patients. Percentage of ILC2 c-Kit− and c-Kit+ for
HD and metastatic colorectal cancer patients at baseline and after treatment (TT).
Columns, the means of ILC2 for each patient; bars, SEM. ∗∗∗∗p < 0.0001, NS
(non-significant) as determined by Student’s t-test.
Figure S3 | Progression-Free Survival Kaplan-Meier curves of
chemotherapy-naïve metastatic colorectal cancer patients. Patients (n = 73)
stratified by the frequency of total ILCs distributed into low + medium (n = 50) vs.
high (n = 23) terciles.
Table S1 | Clinicobiological characteristics of CRC patients. The table summarizes
the clinicobiological characteristics of CRC patients enrolled in the
“Epitopes-CRC02” trial (NCT02817178) before (baseline) and after chemotherapy
treatment (n = 96).
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